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associations between baseline levels of Tregs and cardiovascular disease
in a large prospective case-cohort sample, embedded in the European
Prospective Investigation into Cancer and Nutrition (EPIC) Heidelberg
cohort, followed-up for 7 years and including 276myocardial infarction
cases and 778 controls (Barth et al., 2016–in this issue). In this study the
DNA demethylation of the Treg-speciﬁc demethylated region (TSDR) ofAdaptive immune responses against self-molecules cause autoim-
mune diseases, such as rheumatoid arthritis, systemic lupus erythema-
tosus, multiple sclerosis and type 1 diabetes. Adaptive immune
responses are coordinated by T helper cells expressing CD4. Normally,
T cells are tightly controlled not to react with self-molecules, but auto-
immunity can be triggered when T cells escape the control mechanisms
that maintain self-tolerance or when self-molecules are altered ormod-
iﬁed beyond what the immune system is trained to recognize as self.
Regulatory T cells (Tregs) are a subpopulation of CD4+ T cells involved
in maintaining immune homeostasis and peripheral tolerance by
counteracting autoimmune responses. Deﬁning characteristics of Tregs
have been the expression of CD25 and the forkhead box P3 transcription
factor (FOXP3), even though these proteins can also be expressed by ac-
tivated conventional CD4+ T cells. More recently, demethylation of a
speciﬁc region in the FOXP3 gene has been associated with stable
FOXP3 expression in Tregs, but not in activated conventional T cells
(Floess et al., 2007).
The disease process in atherosclerosis is driven at least in part by au-
toimmune reactions to self-proteins such as apolipoprotein B and heat
shock proteins and thus a role for Tregs could be anticipated (Nilsson
et al., 2015; Wick et al., 2014). In fact, there is plenty of evidence that
is consistent with Tregs playing a role in atherosclerosis, myocardial in-
farction and a number of other cardiovascular diseases (Meng et al.,
2016). Many studies have found that the number of Tregs are reduced
in patients with unstable coronary artery disease whereas others have
found an increase in Tregs in ST-elevation myocardial infarction
patients (Ammirati et al., 2010; Cheng et al., 2008; Han et al., 2007;
Mor et al., 2006). A large prospective population based cohort study
(n = 700) has also found an association between increased risk of
myocardial infarction and reduced Tregs in the circulation (Wigren
et al., 2012).om.2016.07.035.
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the FOXP3 gene was used to quantify Tregs as ratio of total T cells (tTL),
also determined by an epigenetic signature in the CD3gene. The authors
found that individualswith a low Treg/tTL ratio suffered lessmyocardial
infarctions during follow-up independently of sex. The signiﬁcant asso-
ciation was, however, lost when themodel was supplementedwith ad-
ditional cardiovascular risk factors, such as smoking, hyperlipidemia,
and hypertension, and dietary factors including energy-adjusted dietary
intakes of red and processed meat (Barth et al., 2016–in this issue).
There are many differences between this study and the previous large
prospective study by Wigren et al. (2012). First, Tregs were quantiﬁed
differently, not only in terms of method used, but also the Treg ratio
was reported as percentage of total T cells by Barth et al., whereas
Wigren et al. reports the Treg ratio as a percentage of CD4+ T cells.
Also, the cohorts under study differed, mainly by the fact that Barth et
al. excluded diabetics. In addition, the EPIC cohort was a bit younger
and had less hypertension than the cohort studied byWigren et al. No-
tably, none of the two prospective studies found any associations be-
tween circulating Tregs and stroke. Furthermore, the study by Wigren
et al. found no association between Tregs and the extent of subclinical
atherosclerosis measured as carotid intima media thickness (IMT)
with ultrasound. The lack of association between Tregs and subclinical
atherosclerosis has been conﬁrmed by Ammirati et al. who also did
not ﬁnd any association between carotid IMT at baseline, nor did they
ﬁnd any difference in Tregs between slow and rapid carotid IMT
progressors during 6 years of follow-up (Ammirati et al., 2010).
Assuming that quantiﬁcation of total Tregs using demethylation of
the FOXP3 gene or ﬂow cytometry are correlates of true Tregs, these
studies suggest that circulating Tregs may not be a strong predictor of
myocardial infarction that could translate into a usable predictor in
the clinic. The studies do not, however, speak against the hypothesis
that Tregs play a role in cardiovascular disease as in other autoimmune
diseases. One possibility for the lack of a stronger association between
Tregs and cardiovascular disease could be that total Tregs have a diverse
set of antigen speciﬁcities and perhaps Tregs with a speciﬁcity for anti-
gens relevant in atherosclerosis and cardiovascular disease would be
better predictors of cardiovascular disease. Interestingly, relevant
auto-antigens such as apolipoprotein B and heat shock proteins havethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
16 H. Björkbacka / EBioMedicine 11 (2016) 15–16been deﬁned and evaluated as therapeutic vaccines in animal models
(Nilsson et al., 2015; Wick et al., 2014). It remains to be determined if
antigen-speciﬁc Tregs can be quantiﬁed in human blood and if they
could be used for disease prediction that affects clinical decisionmaking.
It also remains to be determined if monitoring Tregs could be used to
evaluate the efﬁcacy of novel immunomodulatory therapies currently
in development.
In conclusion, regulatory T cells play a protective role in atheroscle-
rosis and cardiovascular disease and they could be important therapeu-
tic targets. Recent data, however, indicates that the fraction of
regulatory T cells in the total T cell compartment has limiteduse for clin-
ically relevant disease prediction.
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